Conferences - Results from #280

ESMO 2024: B7-H3 as Therapeutic Target for Prostate Cancer September 15, 2024

ESMO 2024: Assessment of the Utility of CT Scans in the Long-Term Follow-up of Metastatic Non-Seminomatous Germ Cell Tumors: The Late CT Study September 14, 2024

ESMO 2024: TAMARACK: Randomized Phase 2 Trial of the B7-H3 Targeting Antibody Drug Conjugate Vobramitamab September 14, 2024

ESMO 2024: SAABR: Single Arm Phase II Study of Androgen Receptor Pathway Inhibitor + Atezolizumab + GnRH analog and Stereotactic Body Radiotherapy to the Prostate in Men with De Novo Hormone-sensitive Metastatic Prostate Cancer September 14, 2024

ESMO 2024: Association of PD-L1 Expression with Clinical Response to TAR-200 in the Phase 2b SunRISe-1 Trial September 14, 2024

ESMO 2024: Intensification of Systemic Treatment for Poor Risk Disease September 14, 2024

ESMO 2024: The STAMPEDE2 (177Lu-PSMA-617) Trial: A Phase III, Randomised, Open-Label Trial in Patients with Metastatic Prostate Cancer Starting ADT September 14, 2024

ESMO 2024: The STAMPEDE2 Stereotactic Ablative Body Radiotherapy Trial: A Phase III, Randomized, Open-Label Trial in Patients with Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT September 14, 2024

ESMO 2024: The STAMPEDE2 Niraparib-Abiraterone Acetate + Prednisolone Trial: A Phase III, Randomized, Open-Label Trial in Patients with Metastatic Prostate Cancer with a Deleterious Alteration in a HRR Gene Starting ADT September 14, 2024

ESMO 2024: LEGEND: A Phase 1/2 Study of EG-70 (Detalimogene Voraplasmid) Intravesical Monotherapy for Patients with BCG-Unresponsive NMIBC with CIS September 14, 2024

ESMO 2024: Phase 1/2 Trial of Oral Masofaniten (EPI-7386) in Combination with Enzalutamide Compared to Enzalutamide Alone in Metastatic Castration-Resistant Prostate Cancer September 14, 2024

ESMO 2024: Enzalutamide with or Without Leuprolide in Patients with High-Risk Biochemically Recurrent Prostate Cancer: EMBARK Post Hoc Analysis by Age September 14, 2024

ESMO 2024: PSMA-PET and PROMISE Re-Define Stage and Risk in Patients with Prostate Cancer September 14, 2024

ESMO 2024: Enfortumab Vedotin + Pembrolizumab Outcomes Outside Clinical Trials and Biomarkers of Benefit in Patients with Advanced Urothelial Carcinoma: Analysis of the UNITE Study September 14, 2024

ESMO 2024: Radium-223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Patients with Bone Metastatic Castration-Resistant Prostate Cancer: First Results of EORTC-GUCG 1333/PEACE-3 September 14, 2024

ESMO 2024: RUTIVAC-1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI® in Individuals with High-Risk Non-Muscle-Invasive Bladder Cancer Treated with Intravesical BCG September 14, 2024

ESMO 2024: Invited Discussant – EORTC-GUCG 1333/PEACE-3 September 14, 2024

ESMO 2024: First Results from ZZFIRST: a Randomized Phase II Trial of Enzalutamide with or without Talazoparib in Metastatic Hormone-naïve Prostate Cancer September 14, 2024

ESMO 2024: Xaluritamig, a STEAP1 x CD3 XmAb 2+1 Immune Therapy, in Patients With Metastatic Castration-Resistant Prostate Cancer: Initial Results From Dose Expansion Cohorts in a Phase 1 Study September 14, 2024

ESMO 2024: Symptomatic Skeletal Events, Health-Related Quality of Life and Pain in a Phase 3 Study of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer: Third Interim Analysis of PSMAfore September 14, 2024

Page 15 of 594